health
Moderna shares double on skin cancer vaccine success
Drugmaker’s melanoma shot developed with Merck delivers positive outcome in late-stage trial
TL;DR
- Moderna's melanoma vaccine, co-developed with Merck, has shown positive results in late-stage trials.
- The success of the vaccine caused Moderna's shares to double.
- This represents a significant step forward in melanoma treatment.